WebMyozyme [package insert]. Cambridge, MA: Genzyme Corp; 2012. Activase [package insert]. San Francisco, CA: Genentech; 2011. Cathflo Activase[package insert]. San Francisco, CA: Genentech; 2010. Aminophylline [package insert]. Shirley, NY: American Regent Laboratories, Inc; 1999. Aminophylline dihydrate [package insert]. Web24 hours at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. Discard unused EXONDYS 51. 2.3 . Administration Instructions . Application of a topical anesthetic cream to the infusion site …

Myozyme European Medicines Agency

WebFDA-approved indication: Myozyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for use in patients with Pompe disease (GAA deficiency). Myozyme … WebMYOZYME® (alglucosidase alfa) is indicated for use in patients with Pompe’s Disease (GAA deficiency). MYOZYME® has been shown to improve ventilator-free survival in patients … tax office 77089

Infanrix: Package Insert - Drugs.com

WebJan 6, 2010 · Myozyme (package insert). Cambridge, MA: Genzyme Corporation; 2006. Google Scholar; 13. ... Myozyme™, has now been approved by the U.S. Food and Drug Administration and the European Union as therapy for Pompe disease. Duke University and inventors for the method of treatment and predecessors of the cell lines used to generate … WebOct 11, 2012 · Although enzyme replacement therapy with alglucosidase alfa (Myozyme) in Pompe disease has improved the prognosis of this otherwise lethal disorder, patients who develop high sustained antibody... WebThis package insert is continually updated: Please read carefully before using a new pack. MYOZYME® Alglucosidase alfa for Injection (r-DNA origin) Lyophilized Powder for concentrate for solution for Intravenous infusion 1. NAME OF THE MEDICINAL PRODUCT Myozyme® (alglucosidase alfa) 50 mg lyophilized powder for concentrate for solution for the cliche